A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer

Background - Neoadjuvant systemic therapy (NST) before surgery is a standard option for patients with early breast cancer (EBC) that allows in vivo chemosensitivity testing. Given the promising activity of pemetrexed plus doxorubicin in metastatic breast cancer, it was reasonable to evaluate the uti...

Full description

Bibliographic Details

Main Authors:	Schneeweiss, Andreas (Author) , Marmé, Frederik (Author) , Ruiz, A. (Author) , Manikhas, A. G. (Author) , Bottini, A. (Author) , Wolf, M. (Author) , Sinn, Peter (Author) , Mansouri, K. (Author) , Kennedy, L. (Author) , Bauknecht, T. (Author)
Format:	Article (Journal)
Language:	English
Published:	[March 2011]
In:	Annals of oncology Year: 2011, Volume: 22, Issue: 3, Pages: 609-617
ISSN:	1569-8041
DOI:	10.1093/annonc/mdq400
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/annonc/mdq400 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753419386004
Author Notes:	A. Schneeweiss, F. Marmé, A. Ruiz, A. G. Manikhas, A. Bottini, M. Wolf, H. -P. Sinn, K. Mansouri, L. Kennedy & T. Bauknecht